Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
Abstract In the BrighTNess trial, carboplatin added to neoadjuvant chemotherapy (NAC) was associated with increased pathologic complete response (pCR) rates in patients with stage II/III triple-negative breast cancer (TNBC). In this matched cohort study, cases with a germline BRCA1/2 mutation (gBRCA...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/c6af5c9ea1394c7ab85bf5141ac651b6 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:c6af5c9ea1394c7ab85bf5141ac651b6 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:c6af5c9ea1394c7ab85bf5141ac651b62021-11-14T12:31:48ZMatched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness10.1038/s41523-021-00349-y2374-4677https://doaj.org/article/c6af5c9ea1394c7ab85bf5141ac651b62021-11-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00349-yhttps://doaj.org/toc/2374-4677Abstract In the BrighTNess trial, carboplatin added to neoadjuvant chemotherapy (NAC) was associated with increased pathologic complete response (pCR) rates in patients with stage II/III triple-negative breast cancer (TNBC). In this matched cohort study, cases with a germline BRCA1/2 mutation (gBRCA; n = 75) were matched 1:2 with non-gBRCA controls (n = 150) by treatment arm, lymph node status, and age to evaluate pCR rates and association of benefit from platinum/PARP inhibitors with validated RNA expression-based immune, proliferation, and genomic instability scores among gBRCA with the addition of carboplatin ± veliparib to NAC. Among the well-matched cohorts, odds of pCR were not higher in gBRCA cancers who received standard NAC with carboplatin (OR 0.24, 95% CI [0.04-1.24], p = 0.09) or with carboplatin/veliparib (OR 0.44, 95% CI [0.10-1.84], p = 0.26) compared to non-gBRCA cancers. Higher PAM50 proliferation, GeparSixto immune, and CIN70 genomic instability scores were each associated with higher pCR rate in the overall cohort, but not specifically in gBRCA cases. In this study, gBRCA carriers did not have higher odds of pCR than non-gBRCA controls when carboplatin ± veliparib was added to NAC, and showed no significant differences in molecular, immune, chromosomal instability, or proliferation gene expression metrics.Otto Metzger-FilhoKatharine CollierSarah AsadPeter J. AnsellMark WatsonJunu BaeMathew CherianJoyce O’ShaughnessyMichael UntchHope S. RugoJens B. HuoberMehra GolshanWilliam M. SikovGunter von MinckwitzPriya RastogiLang LiLijun ChengDavid MaagNorman WolmarkCarsten DenkertW. Fraser SymmansCharles E. GeyerSibylle LoiblDaniel G. StoverNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-6 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Otto Metzger-Filho Katharine Collier Sarah Asad Peter J. Ansell Mark Watson Junu Bae Mathew Cherian Joyce O’Shaughnessy Michael Untch Hope S. Rugo Jens B. Huober Mehra Golshan William M. Sikov Gunter von Minckwitz Priya Rastogi Lang Li Lijun Cheng David Maag Norman Wolmark Carsten Denkert W. Fraser Symmans Charles E. Geyer Sibylle Loibl Daniel G. Stover Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness |
| description |
Abstract In the BrighTNess trial, carboplatin added to neoadjuvant chemotherapy (NAC) was associated with increased pathologic complete response (pCR) rates in patients with stage II/III triple-negative breast cancer (TNBC). In this matched cohort study, cases with a germline BRCA1/2 mutation (gBRCA; n = 75) were matched 1:2 with non-gBRCA controls (n = 150) by treatment arm, lymph node status, and age to evaluate pCR rates and association of benefit from platinum/PARP inhibitors with validated RNA expression-based immune, proliferation, and genomic instability scores among gBRCA with the addition of carboplatin ± veliparib to NAC. Among the well-matched cohorts, odds of pCR were not higher in gBRCA cancers who received standard NAC with carboplatin (OR 0.24, 95% CI [0.04-1.24], p = 0.09) or with carboplatin/veliparib (OR 0.44, 95% CI [0.10-1.84], p = 0.26) compared to non-gBRCA cancers. Higher PAM50 proliferation, GeparSixto immune, and CIN70 genomic instability scores were each associated with higher pCR rate in the overall cohort, but not specifically in gBRCA cases. In this study, gBRCA carriers did not have higher odds of pCR than non-gBRCA controls when carboplatin ± veliparib was added to NAC, and showed no significant differences in molecular, immune, chromosomal instability, or proliferation gene expression metrics. |
| format |
article |
| author |
Otto Metzger-Filho Katharine Collier Sarah Asad Peter J. Ansell Mark Watson Junu Bae Mathew Cherian Joyce O’Shaughnessy Michael Untch Hope S. Rugo Jens B. Huober Mehra Golshan William M. Sikov Gunter von Minckwitz Priya Rastogi Lang Li Lijun Cheng David Maag Norman Wolmark Carsten Denkert W. Fraser Symmans Charles E. Geyer Sibylle Loibl Daniel G. Stover |
| author_facet |
Otto Metzger-Filho Katharine Collier Sarah Asad Peter J. Ansell Mark Watson Junu Bae Mathew Cherian Joyce O’Shaughnessy Michael Untch Hope S. Rugo Jens B. Huober Mehra Golshan William M. Sikov Gunter von Minckwitz Priya Rastogi Lang Li Lijun Cheng David Maag Norman Wolmark Carsten Denkert W. Fraser Symmans Charles E. Geyer Sibylle Loibl Daniel G. Stover |
| author_sort |
Otto Metzger-Filho |
| title |
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness |
| title_short |
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness |
| title_full |
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness |
| title_fullStr |
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness |
| title_full_unstemmed |
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness |
| title_sort |
matched cohort study of germline brca mutation carriers with triple negative breast cancer in brightness |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/c6af5c9ea1394c7ab85bf5141ac651b6 |
| work_keys_str_mv |
AT ottometzgerfilho matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT katharinecollier matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT sarahasad matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT peterjansell matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT markwatson matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT junubae matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT mathewcherian matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT joyceoshaughnessy matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT michaeluntch matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT hopesrugo matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT jensbhuober matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT mehragolshan matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT williammsikov matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT guntervonminckwitz matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT priyarastogi matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT langli matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT lijuncheng matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT davidmaag matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT normanwolmark matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT carstendenkert matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT wfrasersymmans matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT charlesegeyer matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT sibylleloibl matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness AT danielgstover matchedcohortstudyofgermlinebrcamutationcarrierswithtriplenegativebreastcancerinbrightness |
| _version_ |
1718429192515747840 |